Video Experimental Relacionado
Updated: Jun 10, 2026
09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
La liberación autónoma de fármacos anticancerígenos in vitro de nanopartículas de sílice mesoporosa por nanovalvas
1Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, California 90095, USA.
Journal of the American Chemical Society
|August 20, 2010
Resumen
Las nuevas nanopartículas de sílice mesoporosa (MSNP) utilizan nanovalvas de beta-ciclodextrina (beta-CD) para la administración de fármacos dirigidos. Estas nanovalvas responden a las condiciones celulares, permitiendo la liberación controlada de terapias como la doxorubicina dentro de las células cancerosas.
Área de la Ciencia:
- Nanotecnología La nanotecnología es la nanotecnología.
- Ciencia de los materiales Ciencia de los materiales.
- Ingeniería Biomédica Ingeniería Biomédica.
Sus antecedentes:
- Las nanopartículas de sílice mesoporosa (MSNP) son soportes sólidos efectivos para la administración controlada de medicamentos.
- La funcionalidad de superficie de MSNP permite el control de las aberturas de nanoporo para la liberación de carga.
- Los sistemas MSNP anteriores entregaban carga en condiciones abióticas utilizando nanovalvas.
Objetivo del estudio:
- Adaptar los sistemas de administración de fármacos MSNP para aplicaciones biológicas.
- Desarrollar MSNP con nanovalvas que responden a las condiciones intracelulares.
- Para investigar las nanovalvas de beta-ciclodextrina (beta-CD) para desencadenar la liberación de fármacos en las células cancerosas.
Principales métodos:
- MSNP diseñado y funcionalizado con nanovalvas de beta-ciclodextrina (beta-CD).
- Respuesta probada de las nanovalvas a la acidificación endosómica en líneas celulares THP-1 y KB-31.
- Superficie MSNP optimizada para la liberación eficiente de doxorubicina a los núcleos celulares KB-31.
Principales resultados:
- Se ha demostrado la apertura de la nanovalva beta-CD en respuesta a la acidificación endosómica.
- Se logra la liberación controlada de doxorubicina del MSNP dentro de las células cancerosas.
- Funcionalidad de superficie MSNP optimizada para la entrega rápida de drogas nucleares.
Conclusiones:
- Desarrolló un nuevo sistema de administración de fármacos MSNP utilizando nanovalvas beta-CD sensibles al pH.
- Valida la eficacia del sistema en la administración de fármacos a los núcleos de las células cancerosas.
- MSNP con nanovalvas a medida ofrecen una plataforma prometedora para la terapia dirigida contra el cáncer.
Videos de Conceptos Relacionados
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.